| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Urology* and the Division of Medical Biochemistry,¶ Innsbruck Medical University, Innsbruck, Austria; the Departments of Pathology and Urology, General Hospital Feldkirch, Feldkirch, Austria; and the Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy
Interleukin-6, levels of which are elevated in prostate cancer, activates different signal transduction pathways including that of Janus kinases/signal transducer and activator of transcription (STAT)3. However, phosphorylation of STAT3 has been reported to be associated with either stimulatory or inhibitory effects on cellular proliferation. To better understand the mechanisms of STAT3 regulation in benign and malignant prostate, we have investigated the role of suppressor of cytokine signaling (SOCS)-3. Cell lines that did not express phosphorylated STAT3 were found to be SOCS-3-positive. SOCS-3 was re-expressed in LNCaP cells after treatment with a demethylating agent. SOCS-3 immunohistochemistry revealed a negative or weak reaction in benign areas, whereas its expression was detected in tumor tissue. To investigate the involvement of SOCS-3 in regulation of cellular events, we incubated cancer cells with a cAMP derivative. This treatment yielded higher SOCS-3 levels, reduced [3H]thymidine incorporation, and increased percentage of apoptotic cells. However, down-regulation of SOCS-3 by a short interfering RNA approach resulted in inhibition of proliferation and an increased apoptotic rate. Collectively, our results show that SOCS-3 antagonizes regulation of cellular events by cAMP and is expressed in human prostate cancer.
This article has been cited by other articles:
 |
|
 |
|
  M. E. HANDEL-FERNANDEZ, D. ILKOVITCH, V. IRAGAVARAPU-CHARYULU, L. M. HERBERT, and D. M. LOPEZ Decreased Levels of Both Stat1 and Stat3 in T Lymphocytes from Mice Bearing Mammary Tumors Anticancer Res, June 1, 2009; 29(6): 2051 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. PITULIS, E. PAPAGEORGIOU, R. TENTA, P. LEMBESSIS, and M. KOUTSILIERIS IL-6 and PPAR{gamma} Signalling in Human PC-3 Prostate Cancer Cells Anticancer Res, June 1, 2009; 29(6): 2331 - 2337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Neuwirt, M. Puhr, F. R. Santer, M. Susani, W. Doppler, G. Marcias, V. Rauch, M. Brugger, A. Hobisch, L. Kenner, et al. Suppressor of Cytokine Signaling (SOCS)-1 Is Expressed in Human Prostate Cancer and Exerts Growth-Inhibitory Function through Down-Regulation of Cyclins and Cyclin-Dependent Kinases Am. J. Pathol., May 1, 2009; 174(5): 1921 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Malinowska, H. Neuwirt, I. T Cavarretta, J. Bektic, H. Steiner, H. Dietrich, P. L Moser, D. Fuchs, A. Hobisch, and Z. Culig Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor Endocr. Relat. Cancer, March 1, 2009; 16(1): 155 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Qin, S. A. Niyongere, S. J. Lee, B. J. Baker, and E. N. Benveniste Expression and Functional Significance of SOCS-1 and SOCS-3 in Astrocytes J. Immunol., September 1, 2008; 181(5): 3167 - 3176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Neuwirt, M. Puhr, I. T Cavarretta, M. Mitterberger, A. Hobisch, and Z. Culig Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion Endocr. Relat. Cancer, December 1, 2007; 14(4): 1007 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Qin, K. L. Roberts, S. A. Niyongere, Y. Cong, C. O. Elson, and E. N. Benveniste Molecular Mechanism of Lipopolysaccharide-Induced SOCS-3 Gene Expression in Macrophages and Microglia J. Immunol., November 1, 2007; 179(9): 5966 - 5976. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
